Table 1 Baseline demographics and disease characteristic of the patients
Characteristic | Dose groups | |||
|---|---|---|---|---|
A (0.6Â mg) | B (1.2Â mg) | C (1.8Â mg) | D (2.4Â mg) | |
Age (years), median | 54.00 | 56.50 | 46.50 | 58.00 |
Gender n (%) | ||||
 Female | 0(0.00%) | 2(33.33%) | 4(66.67%) | 3(50.00%) |
 Male | 3(100.00%) | 4(66.67%) | 2(33.33%) | 3(50.00%) |
Height (cm), Mean (SD) | 171.33 (6.35) | 167.17 (5.31) | 163.67 (6.09) | 169.00 (8.99) |
Weight (kg), mean (SD) | 70.67 (16.92) | 72.17 (11.02) | 67.67 (16.72) | 72.08 (9.97) |
BSA (cm2), Mean (SD) | 1.82 (0.24) | 1.80 (0.14) | 1.70 (0.18) | 1.82 (0.17) |
ECOGa PFS n (%) | ||||
 0 | 1(33.33%) | 2(33.33%) | 1(16.67%) | 1(16.67%) |
 1 | 2(66.67%) | 4(66.67%) | 5(83.33%) | 5(83.33%) |
Histological type n (%) | ||||
 Squamous | 1(33.33%) | 1(16.67%) | 0(0.00%) | 0(0.00%) |
 Adenocarcinoma | 2(66.67%) | 5(83.33%) | 6(100.00%) | 6(100.00%) |
First-line chemotherapy with cisplatin/carboplatin-based combination | ||||
 No. of Cycles (SD) | 5.33 (0.94) | 6.67 (1.15) | 4.87 (1.21) | 5 (1.53) |
 Reaction to Chemotherapy, PR/SDb | 2/1 | 3/3 | 1/5 | 2/4 |